

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 200 404 B1

(12)

EUROPEAN PATENT SPECIFICATION(45) Date of publication of patent specification: 30.06.93 (51) Int. Cl.⁵: **C07K 1/04, C07K 7/00**(21) Application number: **86302731.4**(22) Date of filing: **11.04.86** ✓(54) **Solid phase process for synthesizing peptides.** ✓(30) Priority: **11.04.85 US 722218**
09.04.86 US 849835(43) Date of publication of application:
05.11.86 Bulletin 86/45(45) Publication of the grant of the patent:
30.06.93 Bulletin 93/26(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE(56) References cited:
DE-A- 2 212 787
US-A- 4 478 984

THE JOURNAL OF ORGANIC CHEMISTRY, vol. 50, no. 25, 13th December 1985, pages 5291-5298, American Chemical Society;
J.P.TAM: "A gradative deprotection strategy for the solid-phase synthesis of peptide amides using p-(Acyloxy)benzhydrylamine resin and the SN2 deprotection method"

CHEMISCHE BERICHTE, vol. 103, no. 7, 1970, pages 2041-2051, Verlag Chemie GmbH, Weinheim, DE; **W.KÖNIG et al.**: "Eine neue Amid-Schutzgruppe"

HELVETICA CHIMICA ACTA, vol. 54, Fasc. 8, 1971, pages 2772-2775; **P.RIVAILLE et al.**: "Synthèse en phase solide de l'hormone de libération de l'hormone lutéotrophique (LH-RH)"

CHEMICAL COMMUNICATIONS, (The Journal of the Chemical Society, Section D), no. 11, 10th June 1970, pages 650-651; **P.G.PIETTA et al.**: "Amide protection and amide supports in solid-phase peptide synthesis"

(73) Proprietor: **ALPHA-1 BIOMEDICALS, INC.** ✓
777 14th Street, N.W. Suite 774
Washington, D.C. 20005(US)(72) Inventor: **Wang, Su Sun**
1512 Chula Vista Drive
Belmont California 94002(US)(74) Representative: **Adams, William Gordon et al**
RAWORTH, MOSS & COOK 36 Sydenham
Road
Croydon Surrey CR0 2EF (GB)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Description

This invention relates to an improved process for synthesis of peptides by the solid phase method. More particularly, the invention relates to the synthesis of peptide amides by solid phase peptide synthesis using a novel resin support, methylbenzhydrylamine resin, and hydrogen bromide as the cleavage and deprotecting agent for separating the resin-bound peptide from the resin support. In a particular aspect, the invention relates to the solid phase synthesis of thymosin α_1 .

The function of peptides in human health has received much recognition in recent years, see, e.g. "Peptides: A Medical Rediscovery" by Joseph Alper, High Technology, Vol. 3, No. 9, September 1983, pages 60-63. Peptides have been shown to function, for example, as hormones for regulating growth, reproduction, and immunology, and as neurotransmitters. While actual and positive biological results have been observed for several dozens of different peptides, still much work remains to be done to determine how the peptides work in the body. For this purpose, large quantities of the peptides are required. Also, in order for the peptides of known biological activity to be of practical significance in health care, they must be made readily available in large quantities and at relatively low cost.

In addition to the "natural" peptides, i.e. those produced in the body, "synthetic" peptides or analogs, which may be considered as derivatives of natural peptides, but having one or more chemical modifications in the molecular structure of the natural peptide, are also valuable for their modified chemical properties, such as resistance to enzyme degradation. Here again, the availability of relatively inexpensive means to rapidly and inexpensively produce synthetic peptides would be highly valuable.

Presently, various procedures for synthesizing peptides, i.e. for formation of a peptide linkage between amino acids, are known. Conventional procedures include both solution-phase (or liquid phase) methods and solid-phase methods. A general discussion of peptide synthesis can be found, for example, in Schroder E. Lubke: "The Peptides," Vol. 1 (1966), Academic Press, New York, U.S.A. and Neurath and Hill, "The Proteins," Vol. 2 (1976), Academic Press, New York, U.S.A. Generally, these procedures involve the reaction between the free amino group of an amino acid or residue thereof having its carboxyl group, hydroxyl group or other reactive group(s) protected, and the free primary carboxylic group of another amino acid or residue thereof having its amino group or other reactive group(s) protected to form a peptide bond. Each amino acid in the desired sequence can be added singly successively to another amino acid or residue thereof or separate peptide fragments with the desired amino acid sequence can be synthesized and then condensed to provide the desired peptide.

In the past ten to twenty years the synthesis of peptides has been simplified by utilizing the solid phase synthesis method according to the general principles developed by Merrifield, [R.B. Merrifield, J. Am. Chem. Soc. 85, 2149-2154 (1963); Stewart, et al, Solid Phase Peptide Synthesis, Freeman & Co., San Francisco, CA (1969); Barany, et al, The Peptides, Analysis, Synthesis and Biology, Vol. 2, pages 1-284, (1980)]. Briefly in solid-phase peptide synthesis (SPPS), the carboxyl group of the first amino acid in a peptide is chemically bound to the surface of tiny, insoluble beads, with the other reactive sites on the amino acid being temporarily blocked. The amino acid-bound resin beads are placed in a reaction vessel and unbound acid is washed away. After chemically unblocking the reactive amino group, the next amino acid in the desired sequence of the object peptide is added with a chemical coupling agent such that the two acids bind together, via a peptide bond. The synthesis is continued by repeating the foregoing process with successive amino acids in the sequence being added one at a time until the total peptide sequence is built up on the resin. Upon completion of the desired peptide sequence, the protected peptide is cleaved from the resin support, and all protecting groups are removed. The cleavage reaction and removal of protecting groups may be accomplished simultaneously or sequentially.

SPPS has recently been adapted to automated and computerized instrumentation offering substantial improvements in speed, efficiency, and reliability. However, the use of such instrumentation has been substantially limited to production of peptides on a relatively small scale, on the order of a few milligrams per production cycle. Also, the procedure inherently results in the production of unwanted by-products, unreacted acids, solvents, coupling or decoupling agents, cleavage products and so on, making the subsequent purification procedures troublesome.

Although the art is aware of various different materials used as the insoluble beads, including glass, silica, synthetic resins, etc., the synthetic resins are most commonly used as the support material (insoluble beads). Conventional materials used as the resin include the styrene-divinyl benzene resin modified with a reactive group, such as chloromethylated styrene-divinyl benzene resin and benzhydrylamine resin (BHA). BHA is particularly useful for synthesis of peptide amides, i.e. peptides of which the C-terminal amino acid has a carboxylamide ($-\text{CONH}_2$) group, since the amide group can be formed directly. The benzhydrylaminopolystyrenedivinyl benzene resin support is described by P. Rivaille, et al, *Helv. Chim. Acta.*,

54, 2772 (1971).

Hydrogen fluoride, HF, is commonly used as the cleavage agent, and also as the deprotecting agent for removing the various blocking groups.

Unfortunately, HT, whether in liquid, anhydrous, or gaseous form, is highly corrosive and toxic requiring special handling and special plastic materials. As a result, the scale-up of the SPPS procedure from the laboratory scale to commercial scale production (e.g. on the order of one or more grams per production run) has proven extremely difficult.

It has been known to use the less corrosive and less toxic hydrogen bromide (HBr) in place of HT as the cleavage agent, alone, or together with anisole as a catalyst for cleaving the bound protected peptide from the supporting resin. However, HBr alone or with anisole does not function effectively as a cleavage agent with BHA resin, apparently due to the relatively high acid stability of BHA resin.

Accordingly, there is a great need to provide a method whereby peptides can be produced economically and simply using chemical substances which are non-corrosive to ordinary laboratory glasswares and of relatively low toxicity and which can produce the peptides on a commercial scale.

This invention seeks to provide a safe, simple method for producing peptides by the solid phase peptide synthesis method which avoids the use of highly corrosive and toxic hydrogen fluoride.

The invention also seeks to produce peptides according to the SPPS method which can be scaled up to commercial scale production, and which uses ordinary laboratory glassware, plastics, etc., for handling, storing, and transporting all of the chemicals required for the process, including the cleavage and deprotecting agent.

Further the invention seeks the production of peptides by the SPPS method in which the cleavage step results in less side reactions and produces fewer unwanted by-products, thereby greatly simplifying the subsequent purification step(s).

Still further the invention seeks to provide a solid phase peptide synthesis method in which the yield of peptide at the cleavage step is improved over the conventional processes using HF or HBr with anisole.

Specifically this invention seeks to provide an improved process for synthesizing thymosin α_1 by solid phase peptide synthesis using HBr as the cleavage and deprotecting agent for synthesizing thymosin α_1 .

The invention will become apparent from the following detailed description and specific embodiments which provides a solid phase peptide synthesis process for producing a peptide amide having the amino acid sequence represented by the formula Y_p-X-NH_2 , where Y_p represents the N-terminal peptide fragment having at least 2 amino acids bonded together by peptide bonds, and $X-NH_2$ represents the C-terminal amino acid having an amide group ($-CONH_2$) in its molecular structure by forming the peptide having the above sequence bonded to a resin, said peptide optionally having one or more protected functional groups and cleaving the peptide from the resin and deprotecting protected functional groups, characterised in that the peptide is formed by bonding to methylbenzhydrylamine resin and cleaving and deprotecting the resin bound peptide with hydrogen bromide.

In accordance with a preferred embodiment of the invention, the cleavage step is carried out in trifluoroacetic acid in the presence of anisole.

In accordance with a more preferred embodiment of the invention, the cleavage step is carried out in the presence of a mixture of anisole and thioanisole whereby the yields of peptide are substantially improved and production of unwanted by-products substantially reduced.

In a specific embodiment the present invention provides a solid phase synthesis of the thymosin α_1 , polypeptide having the sequence:


Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-
Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-
Glu-Asn-OH

by forming the polypeptide having the above sequence anchored to a resin, said polypeptide optionally having one or more protected functional groups; and cleaving the polypeptide from the resin and deprotecting protected functional groups of the polypeptide; characterised by using methylbenzhydrylamine resin and cleaving and deprotecting the polypeptide by contacting the polypeptide with hydrogen bromide.


Although it has long been known to use hydrogen bromide as the cleavage agent for cleaving the peptide-resin bond in the solid phase protein synthesis method the use of HBr has been limited to certain resin supports, primarily chloromethylated polystyrene-divinylbenzene; HBr does not, however, effectively function as the cleavage or deprotecting agent with benzhydrylamine resin.

The present invention is based on the surprising discovery that by using methylbenzhydrylamine resin as the resin support the cleavage of the bound peptide from the support can be performed using hydrogen bromide as the cleaving agent with a high yield and high degree of specificity of cleavage and deprotecting, not possible with benzhydrylamine resin. Furthermore, the yield of peptide is substantially increased when the deprotecting and cleavage with HBr is carried out in the presence of anisole and still further improvements are achieved according to the present invention by using a mixture of anisole and thioanisole.


Details of the invention will be described below in connection with the production of thymosin α_1 . It should be understood, however, that the methylbenzhydrylamine resin support can be used in the production of any peptide the C-terminal amino acid of which includes an amide radical group, such as asparagine (Asn) (α -aminosuccinamic acid)



and glutamine (Gln),




or generally, any amino acid in which the carboxylic acid group is modified to an amide group. An example of a peptide falling in the latter group is the calcitonin peptide in which the N-terminal (position 32) amino acid is Pro-NH₂, i.e.



where ... represents the residue of the peptide at positions 1-31 (see e.g. U.S. Patent 4,217,268 for a disclosure of the complete structure of calcitonin and its des-X² derivatives, as well as the solid phase synthesis thereof using benzhydrylamine resin support and HT cleavage/deprotection). In general, any peptide which can be produced by solid phase synthesis on benzhydrylamine (BHA) resin support can be produced with the methylbenzhydrylamine (MBHA) resin support according to the present invention. In addition to thymosin α_1 and calcitonin mentioned above, representative of other known peptides which can be produced by the improved procedure of this invention include oxytocin, vasopressin, LH-RH antagonists (see e.g. U.S. Patent 4,431,635, U.S. Patent 4,530,920), the glutamine (Gln) terminated synthetic hormone-like peptides disclosed in U.S. Patent 4,389,342, etc. Also, fragments of peptides which have the -CONH₂ groups can be synthesized by the solid phase synthesis method using MBHA resin support and HBr cleavage. For instance, mention can be made, for example, of the biologically active peptides which are fragments of the sauvagine peptide disclosed in USP 4,474,765; fragment 521:Ala-Ser-Pro-Ser-Gln of the Fc region of immunoglobulin E (IgE) useful in blocking mammalian allergic reaction (disclosed in U.S. Patent 4,161,522); peptide fragments of formulas (VI), (VII), (IX), (X), (XI), (XV), and (SVI) of U.S. Patent 4,497,801, etc.

Accordingly, it should be understood that the improved solid phase peptide synthesis of this invention is applicable to the production of any peptide having an amide (-CONH₂) radical as part of the C-terminal amino acid whether in the form of a "naturally" occurring amino acid, e.g. asparagine (Asn) or glutamine (Gln) or as an amino-group substituted amino acid, the amino-group substituent replacing the hydroxyl group of a carboxylic acid radical. Thus, the peptides produced by the improved SPPS method of this invention may be generally referred to as peptide amides and may be represented by the formula



where

Y_p represents the N-terminal peptide fragment and

$X-NH_2$ represents the C-terminal amino acid having an amide group ($-CONH_2$).

It is understood that peptide sequences are written according to the generally accepted convention whereby the N-terminal amino acid is on the left and the C-terminal amino acid is on the right. The N-terminal peptide fragment Y_p will have at least two, preferably at least 3, amino acids bonded together by peptide bonds, $-CONH-$. There is no particular upper limit to the number of amino acids in the Y_p peptide fragment. For instance, it is possible to use SPPS methodology to synthesize peptides containing as many as 40 or more amino acids, and polypeptides containing, for example, up to about 50 or 60 or more amino acids can be synthesized. In the C-terminal amino acid represented by $X-NH_2$, X may be any of the well known and reasonably accessible amino acids as described, for example, in general textbooks on peptide chemistry; for instance, see K.D. Kopple, "Peptides and Amino Acids," W.A. Benjamin, Inc., New York, 1966, pp. 4-7. Furthermore, the optically active amino acids may be in either the D-, or DL- form.

The methylbenzhydrylamine resin used in the subject invention is prepared from commercially available polystyrene resin beads (1% divinyl benzene, 200-400 mesh U.S. Standard) by reacting the same with p-toluoyl chloride in the presence of a Lewis acid such as aluminum chloride in an inert solvent such as dichloroethane at a low temperature, preferably 0 to 5°C to form a p-toluoyl resin, $CH_3-C_6H_4-CO-C_6H_4$ -resin. This resin is reacted with a mixture of ammonium formate, formamide and formic acid at reflux temperature (160°-170°C) for 24 hours to yield N-formyl methylbenzhydrylamine resin, $CH_3-C_6H_4-CH(NH-CO-H)-C_6H_4$ -resin. Upon hydrolysis in dilute hydrochloric acid, the desired methylbenzhydrylamine resin, i.e. $CH_3-C_6H_4-CH(NH_2 \cdot HCl)-C_6H_4$ -resin, is formed.

According to a specific embodiment of the invention, thymosin α_1 having the following sequence

Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-
Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-
Val-Val-Glu-Glu-Ala-Glu-Asn-OH

is produced by solid phase peptide synthesis using the so-produced methylbenzhydrylamine resin.

The methylbenzhydrylamine resin so formed is neutralized and acylated with $N\alpha$ -Boc- α -benzyl-L-aspartic acid in the presence of dicyclohexylcarbodiimide to give Boc-asparaginyll resin. The solid phase synthesis is then continued by the sequential incorporation of one amino acid unit in each cycle to form a peptide unit which is acetylated to give an acetylated octacosapeptide resin of the structure:

Ac-Ser(Bzl)-Asp(OBzl)-Ala-Ala-Val-Asp(OBzl)-
Thr(Bzl)-Ser(Bzl)-Ser(Bzl)-Glu(OBzl)-Ile-Thr(Bzl)-
Thr(Bzl)-Lys(ClZ)-Asp(OBzl)-Leu-Lys(ClZ)-Glu(OBzl)-
Lys(ClZ)-Lys(ClZ)-Glu(OBzl)-Val-Val-Glu(OBzl)-
Glu(OBzl)-Ala-Glu(OBzl)-Asp(NH-CH(C₆H₄-CH₃)-
C₆H₄-resin)-OBzl.

The protected thymosin α_1 -resin so obtained is suspended in trifluoroacetic acid and treated with dry hydrogen bromide gas at ordinary temperature (20°-25°C) for about one hour in order to cleave the polypeptide from the resin and at the same time remove all the protecting groups from the side chains of the amino acid residues. Although hydrogen bromide may be used alone it is preferred to include anisole and, most preferably, a mixture of anisole and thioanisole in the trifluoroacetic acid when treating with dry hydrogen bromide gas. The present inventor has found that when a mixture of HBr, TFA and anisole is used as the deprotecting and cleaving mixture, the yield of thymosin α_1 is increased, by about 50% over the instance when a mixture of only TFA and HBr is used. When a mixture of HBr, TFA, anisole and thioanisole is used, the yield is improved by about 90%. The volume ratio of anisole: thioanisole is preferably from about 20:80 to about 80:20, most preferably about 50:50 (i.e. about 1:1).

The excess acids are then evaporated off at 40 °C under partial vacuum and the anisole and thioanisole are washed off with ether. Crude thymosin α_1 is extracted from the residue with 1% ammonium acetate and desalted on a Sephadex G-10 column using 0.1 N acetic acid as the eluent. Thereafter, the thymosin α_1 may be purified by high pressure liquid chromatography (C_{18} reversed phase column, 5.7x30 cm). When subjected to analytical high pressure liquid chromatography, the so obtained thymosin α_1 behaves identically to reference thymosin α_1 prepared by the fragment condensation method. Moreover, the presently synthesized thymosin α_1 has been found indistinguishable from natural thymosin α_1 and gives satisfactory amino acid analysis.

It is noted that the combination of methylbenzhydrylamine resin and hydrogen bromide must be used in order to obtain the desired results. If benzhydrylamine resin were used as the support resin, hydrogen fluoride must be used in the deprotecting and cleaving step. This represents a significant difference between the method described in U.S. Patent 4,148,788 disclosing the SPPS method for producing thymosin α_1 and the present invention.

In the description above and following, the abbreviations have the following meaning, according to standard customary nomenclature:

Boc, t-butyloxycarboxy; Bzl, benzyl; DCC, dicyclohexylcarbodiimide; Z, benzyloxycarbonyl; TFA, trifluoroacetic acid, and ClZ, 2-chlorobenzyloxycarbonyl.

While specific protecting groups have been employed in describing the preferred embodiment for synthesis of thymosin α_1 , it is within the skill of the art to utilize equivalent conventional protecting groups.

For example, -Ser(R¹) is utilized as the protected form of serine wherein R¹ is a conventional protecting group for the hydroxyl group of the serine residues such as benzyl, acetyl, benzoyl, tert-butyl, trityl, 4-bromobenzyl, 2,6-dichlorobenzyl and benzyloxycarbonyl; -Asp(OR²) is utilized as the protected form of aspartic acid wherein R² is a conventional protecting group for carboxyl groups selected from esters such as aryl esters, particularly phenyl or phenyl substituted with lower alkyl, halo, nitro, thio or substituted thio, i.e., methylthio, aralkyl esters such as benzyl or benzyl substituted with methoxy, halo or nitro, lower alkyl esters such as methyl, ethyl, tert-butyl and tert-amyl, substituted lower alkyl esters such as 2-haloethyl, β , β -dimethylaminoethyl and cyanomethyl, benzhydryl esters and phenacyl esters; -Thr(R¹) - is utilized as the protected form of threonine wherein R¹ is as defined above; -Glu(OR²) is utilized as the protected form of glutamic acid wherein R² is as defined above; -Lys(R³) is utilized as the protected form of lysine wherein R³ is a conventional ω -amino protecting group selected from benzyloxycarbonyl which may be optionally substituted in the aromatic ring such as by 2-chloro, 4-chloro, 2-bromo, 4-bromo, 2,4-dichloro, 4-nitro, 4-methoxy, 3,5-dimethoxy, 4-methyl, 2,4,6-trimethyl, 4-phenylazo, 4-(4-methoxyphenylazo), 2-(N,N-dimethyl-carbamido), 4-dihydroxyboryl, and 2-nitro-4,5-dimethoxy, other urethane type protecting groups, such as 4-toluenesulfonylethylloxycarbonyl, 9-fluorenylmethylloxycarbonyl and related base cleavable groups, cyclopentylloxycarbonyl and related nitrogen containing urethane groups; acyl groups such as formyl, trifluoroacetyl, phthaloyl, benzenesulfonyl, acetoacetyl, chloroacetyl, 2-nitrobenzoyl, 4-toluene-sulfonyl; and -Asp-OR² is utilized as the protected form of asparagine wherein R² is as defined above.

Although the above description has been given with particular emphasis for the solid phase peptide synthesis of thymosin α_1 , with its specified amino acid sequence and specified protected side chain groups, the practitioner will readily recognize that certain general conditions will preferably be selected regardless of the particular peptide being synthesized. For example, it is well recognized that the α -amino group of each amino acid employed in the peptide synthesis must be protected during the coupling reaction to prevent side reactions involving the reactive α -amino function. Similarly, for those amino acids containing reactive side-chain functional groups (e.g. sulfhydryl, ϵ -amino, hydroxyl, carboxyl), such functional groups need also be protected both during the initial coupling of the amino acid containing the side-chain group and during the coupling of subsequent amino acids. Suitable protecting groups are known in the art [See for example, *Protective Groups in Organic Chemistry*, M. McOmie, Editor, Plenum Press, N.Y., 1973.]

In selecting a particular protecting group, the following conditions must be observed: an α -amino protecting group must: (1) be stable and render the α -amino function inert under the conditions employed in the coupling reaction, and (2) must be readily removable after the coupling reaction under conditions that will not remove the side chain protecting groups or alter the structure of the peptide fragment. A side chain protecting group must: (1) be stable and render the side chain functional group inert under the conditions employed in the coupling reaction, (2) be stable under the conditions employed in removing the α -amino protecting group and (3) be readily removable upon completion of the desired amino acid sequence under reaction conditions that will not alter the structure of the peptide chain, or racemization of any of the chiral centers contained therein. Suitable protecting groups for the α -amino function are t-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz), biphenylisopropylloxycarbonyl, t-amylloxycarbonyl, isobornylloxycarbonyl, 1,1-dimethyl-3,5-dimethoxybenzyloxycarbonyl, o-nitrophenylsulfenyl, 2-cyano-t-butyloxycarbonyl, 9-fluorenyl-

methyloxycarbonyl and the like, especially t-butyloxycarbonyl (Boc).

As examples of carboxyl-protecting groups, there may be mentioned such ester-forming groups as those capable of giving alkyl ester (e.g. methyl, ethyl, propyl, butyl, t-butyl, etc., esters), benzyl ester, p-nitrobenzyl ester, p-methoxybenzyl ester, p-chlorobenzyl ester, benzhydryl ester, etc. and hydrazide-forming groups such as those capable of giving carbobenzoxy hydrazide, t-butyloxy-carbonyl hydrazide, trityl hydrazide, etc.

As groups for protecting the guanidino group of arginine, there may be mentioned nitro, tosyl, p-methoxybenzenesulfonyl, carbobenzoxy, isobornyloxycarbonyl, admantyloxycarbonyl, etc. The guanidino group may also be protected in the form of a salt with an acid (e.g. benzenesulfonic acid, toluene-sulfonic acid, hydrochloric acid, sulfuric acid, etc.).

The hydroxyl group of threonine may be protected, for example, by way of known esterification or etherification. As examples of groups suitable for said esterification, there may be mentioned lower alkanoyl groups (e.g. acetyl), aroyl groups (e.g. benzoyl), and groups derived from carbonic acid, such as benzyloxycarbonyl, ethyloxycarbonyl, etc. As groups suitable for said etherification, there may be mentioned benzyl, tetrahydropyranyl, t-butyl, etc. The hydroxyl group of threonine, however, need not necessarily be protected. Methionine may be protected in the form of a sulfoxide. Other preferred side chain protective groups for particular amino acids include; for tyrosine: benzyl, o-bromobenzyloxycarbonyl, 2,6-dichlorobenzyl, isopropyl, cyclohexyl, cyclopentyl and acetyl; for histidine: benzyl, p-toluenesulfonyl and 2,4-dinitrophenyl; for tryptophan: formyl.

According to the present invention, the production of the peptide amides is carried out using methylbenzhydrylamine (polystyrene-divinyl benzene) resin as the solid support.

The N α -Boc-amino acid or similarly protected C-terminal amino acid is attached to the methyl benzhydrylamine resin by means of an N,N'-dicyclohexylcarbodiimide (DCC)/1-hydroxybenzotriazole (HBT) mediated coupling for from about 2 to about 24 hours, preferably about 12 hours at a temperature of between about 10° and 50° C., preferably 25° C., in a solvent such as dichloromethane or DMF, preferably dichloromethane.

The coupling of successive protected amino acids can be carried out in an automatic polypeptide synthesizer, as well known in the art. Each protected amino acid is preferably introduced in approximately 2.5 or more molar excess and the coupling may be carried out in dichloromethane, dichloromethane/DMF mixtures, DMF and the like, especially in methylene chloride at about ambient temperature. Other solvents which are known to be useful for the purpose of peptide-forming condensation reaction, for example, dimethylsulfoxide, pyridine, chloroform, dioxane, tetrahydrofuran, ethyl acetate, N-methylpyrrolidone, etc., as well as suitable mixtures thereof may also be used.

The reaction temperature for the condensation/coupling reaction may be selected from the range known to be useful for the purpose of peptide-forming condensation reactions. Thus, it may normally be within the range of about -40° C to about 60° C, and preferably, about -20° C to about 0° C. The coupling agent is normally DCC in dichloromethane but may be N,N'-di-iso-propylcarbodiimide or other carbodiimide ether alone or in the presence of HBT, N-hydroxysuccinimide, ethyl 2-hydroxyimino-2-cyanoacetate, other N-hydroxyimides or oximes. Alternatively, protected amino acid active esters (e.g. p-nitrophenyl, pentafluorophenyl and the like) or symmetrical anhydrides may be used.

The coupling, deprotection/cleavage reactions and preparation of derivatives of the polypeptides are suitably carried out at temperatures between about -10° and +50° C, most preferably about 20°-25° C. The exact temperature for any particular reaction will, of course, be dependent upon the substrates, reagents, solvents and so forth, all being well within the skill of the practitioner. The fully deprotected polypeptide may then be purified by a sequence of chromatographic steps employing any or all of the following types: ion exchange on a weakly basic resin in the acetate form; gel permeation chromatography on underivatized polystyrene-divinyl-benzene (for example, Amberlite XAD); silica gel adsorption chromatography; ion exchange chromatography, e.g. on Sephadex G-25, or countercurrent distribution; high performance liquid chromatography (HPLC), especially reverse phase HPLC on octyl- or octadecylsilyl-silica bonded phase column packing.

This invention is further illustrated by the following non-limiting examples.

Example 1

Methylbenzhydrylamine Resin

50.9 gm of polystyrene resin beads (copolystyrene-1%-divinyl benzene, 200-400 mesh beads) was suspended in 500 ml of dichloroethane. The mixture was cooled in an ice-bath with gentle mechanical

stirring until the temperature went below 5°C.

15.5 g of p-toluoyl chloride and 13.3 g of aluminum chloride were mixed in 250 ml of dichloroethane in a dropping funnel. The solution was added dropwise to the cooled, stirred suspension of the resin beads over a period of about 40 min., care being taken not to allow the reaction to warm up above 5°C. The stirring was continued for 4 hours at room temperature when the resin was washed sequentially with isopropanol, isopropanol-water (1:1 mixture), isopropanol and dried to give 53.8 g of p-toluoyl resin. This resin was then mixed with 168 g of ammonium formate, 201 ml of formamide, 134 ml of formic acid and 350 ml of nitrobenzene. The mixture was gradually heated up to 165-170°C under reflux and maintained for 1 day during which time about 115 ml of the aqueous phase was collected into a Dean-Stark trap. The resin was washed and dried as above to yield 55.5 g of N-formyl methylbenzhydrylamine resin. The product was hydrolyzed in a mixture of 300 ml each of 12 N HCl and isopropanol under reflux for 3 hr. Washing and drying the resulting resin provided 54.9 g of the hydrochloride form of methylbenzhydrylamine resin. It showed a very strong positive reaction to ninhydrin reagent and incorporated 0.4 mmol of Boc-Ala-OH when neutralized and coupled with Boc-Ala-OH in the presence of dicyclohexylcarbodiimide.

Example 2

Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-
Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH

(Thymosin α_1)

5.02 gm of methylbenzhydrylamine resin obtained in Example 1 was placed in a peptide synthesis flask equipped with a sintered glass filter at the bottom and a mechanical stirrer at the top. The resin was washed with 20 volumes of 10% triethylamine in methylene chloride and stirred with a fresh portion of the same solution for 10 min. The neutralized methylbenzhydrylamine resin was then reacted with Boc-L-aspartic acid α -benzyl ester (1.95 g, 6 mmol) and dicyclohexylcarbodiimide (1.24 g, 6 mmol) for 2 hours to form Boc- α -benzyl-L-aspartic acyl methylbenzhydrylamine resin. The resin turned from ninhydrin positive to ninhydrin negative after this reaction.

The solid phase peptide synthesis was then continued by performing the following steps wherein in each cycle one amino acid was incorporated sequentially into the growing peptide chain on the resin:

- (1) prewash with 40% trifluoroacetic acid in CH_2Cl_2 ;
- (2) stir for 28 minutes with 40% trifluoroacetic acid;
- (3) three washings with CH_2Cl_2 ;
- (4) prewash with 10% triethylamine in CH_2Cl_2 ;
- (5) stir for 5 minutes with 10% triethylamine;
- (6) wash three times with CH_2Cl_2 ;
- (7) stir for 120 minutes with 6 mmol each of Boc-Glu(OBzl)-OH and DCC;
- (8) wash once with CH_2Cl_2 ;
- (9) wash three times with 50% i-propanol in CH_2Cl_2 ;
- (10) wash three times with CH_2Cl_2 ;
- (11) test for ninhydrin color reaction; if positive, repeat steps 7-11; if negative, go to the next synthetic cycle.

The synthetic cycle was repeated using the following amino acids sequentially and one at a time in step 7 of each cycle: Boc-Ala-OH, Boc-Glu(OBzl)-OH, Boc-Glu(OBzl)-OH, Boc-Val-OH, Boc-Val-OH, Boc-Glu(OBzl)-OH, Boc-Lys(ClZ)-OH, Boc-Lys(ClZ)-OH, Boc-Glu(OBzl)-OH, Boc-Lys(ClZ)-OH, Boc-Leu-OH, Boc-Leu-OH, Boc-Asp(OBzl)-OH, Boc-Lys(ClZ)-OH, Boc-Thr(Bzl)-OH, Boc-Thr(Bzl)-OH, Boc-Ile-OH, Boc-Glu(OBzl)-OH, Boc-Ser(Bzl)-OH, Boc-Ser(Bzl)-OH, Boc-Thr(Bzl)-OH, Boc-Asp(OBzl)-OH, Boc-Val-OH, Boc-Ala-OH, Boc-Ala-OH, Boc-Asp(OBzl)-OH, Boc-Ser(Bzl)-OH, and CH_3COOH . The protected thymosin α_1 -resin so obtained,

Ac-Ser(Bzl)-Asp(OBzl)-Ala-Ala-Val-Asp(OBzl)-Thr(Bzl)-Ser(Bzl)-
 Ser(Bzl)-Glu(OBzl)-Ile-Thr(Bzl)-Thr(Bzl)-Lys(ClZ)-Asp(OBzl)-
 5 Leu-Lys(ClZ)-Glu(OBzl)-Lys(ClZ)-Lys(ClZ)-Glu(OBzl)-Val-Val-Glu-
 (OBzl)-Glu(OBzl)-Ala-Glu(OBzl)-Asp(HN-CH(C₆H₄-CH₃)-C₆H₄-resin)-
 10 OBzl.

weighed 16.8 gm. Part (1.01 gm) of this material was mixed with 2 ml each of anisole and thioanisole and
 16 ml trifluoroacetic acid. A gentle stream of dry HBr gas was bubbled through the magnetically stirred
 15 suspension for 60 minutes at room temperature. The excess acids were then removed by evaporation at
 40°C in a rotary evaporator and the residue washed with ether several times to remove the excess anisole
 and thioanisole. The peptide was extracted into 1% ammonium acetate (2 x 25 ml) and the solution
 desalted on a Sephadex G-10 column (2.6 x 95 cm) using 0.1 M acetic acid as eluant, monitored at 230 nm.
 The material present in the major peak was lyophilized to give 0.33 g of crude product which on purification
 on preparative high pressure liquid chromatography (C₁₈ reverse phase column, eluted with 10-11.25%
 20 CH₃CN in pH 5.0 potassium phosphate buffer) provided 0.10 g of pure thymosin α₁. It has the amino acid
 composition of: Asp, 4.00; Thr, 3.12; Ser, 2.64; Glu, 6.00; Ala, 2.92; Val, 1.92; Ile, 1.04; Leu, 0.96; Lys, 3.98
 (hydrolysis in 6 N HCl, 110°C, 24 hr). The product migrated identically in analytical HPLC with the
 reference compound prepared by the fragment condensation method in solution.

25 Claims

1. A solid phase peptide synthesis process for producing a peptide amide having the amino acid sequence represented by the formula

30 Y_p-X-NH₂

where

Y_p represents the N-terminal peptide fragment having at least 2 amino acids bonded together by peptide bonds, and

35 X-NH₂ represents the C-terminal amino acid having an amide group (-CONH₂) in its molecular structure

by forming the peptide having the above sequence bonded to a resin, said peptide optionally having one or more protected functional groups and cleaving the peptide from the resin and deprotecting protected functional groups, characterised in that the peptide is formed by bonding to methylbenzhydramine resin and cleaving and deprotecting the resin bound peptide with hydrogen bromide.

2. A process of claim 1 wherein the peptide bonded to methylbenzhydramine resin is suspended in trifluoroacetic acid and anhydrous hydrogen bromide gas is blown into the suspension to effect cleavage and deprotection.
3. A process of claim 1 wherein a mixture of hydrogen bromide gas and anisole is used to effect cleavage and deprotection.
4. A method of claim 1 wherein a mixture of hydrogen bromide, anisole and thioanisole is used to effect cleavage and deprotection.
5. A method of claim 4 wherein the volume ratio of anisole to thioanisole is from about 20:80 to about 80:20.
- 55 6. A method of claim 4 wherein the volume ratio of anisole to thioanisole is about 1:1.

7. A solid phase synthesis of the thymosin α_1 , polypeptide having the sequence:

Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-
 Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-
 Glu-Asn-OH

by forming the polypeptide having the above sequence anchored to a resin, said polypeptide optionally having one or more protected functional groups; and cleaving the polypeptide from the resin and deprotecting protected functional groups of the polypeptide; characterised by using methylbenzhydramine resin and cleaving and deprotecting the polypeptide by contacting the polypeptide with hydrogen bromide.

8. A process of claim 7 wherein the methylbenzhydramine resin bound polypeptide is cleaved and deprotected with a mixture of anhydrous hydrogen bromide gas in trifluoroacetic acid.

9. A process of claim 8 wherein the mixture additionally comprises anisole.

10. A process of claim 9 wherein the mixture additionally comprises thioanisole.

11. A process of claim 10 wherein the volume ratio of anisole to thioanisole is from about 1:4 to about 4:1.

12. A process of claim 11 wherein the volume ratio of anisole to thioanisole is about 1:1.

Patentansprüche

1. Peptid-Syntheseverfahren in der festen Phase, um ein Peptidamid mit der Aminosäuresequenz, die durch die Formel



dargestellt wird, herzustellen, wobei

Y_p das mit N endende Peptidfragment bezeichnet, welches mindestens zwei Aminosäuren, verbunden durch Peptidbindungen, aufweist, und

$X-NH_2$, die mit C endende Aminosäure bezeichnet, welche eine Amidgruppe ($-CONH_2$) in ihrer molekularen Struktur besitzt, indem das Peptid gebildet wird, wobei die obenstehende Sequenz an ein Harz gebunden ist, das genannte Peptid auch eine oder Mehrere geschützte Funktionalgruppen besitzen kann, und das Peptid vom Harz gespalten wird und der Schutz von geschützten Funktionalgruppen aufgehoben wird, gekennzeichnet dadurch, daß das Peptid durch Bindung an Methylbenzhydramin-Harz gebildet wird, und das an das Harz gebundenen Peptid mit Wasserstoffbromid abgespalten und der Schutz aufgehoben wird.

2. Verfahren nach Anspruch 1, gekennzeichnet dadurch, daß das an Methylbenzhydramin-Harz gebundene Peptid in Trifluoressigsäure suspendiert wird und anhydriertes Wasserstoffbromidgas in die Suspension geblasen wird um die Abspaltung und die Aufhebung des Schutzes zu bewirken.

3. Verfahren nach Anspruch 1, gekennzeichnet dadurch, daß eine Mischung von Wasserstoffbromidgas und Anisol verwendet wird, um die Abspaltung und die Aufhebung des Schutzes zu bewirken.

4. Verfahren nach Anspruch 1, gekennzeichnet dadurch, daß eine Mischung von Wasserstoffbromid, Anisol und Thioanisol verwendet wird, um die Abspaltung und die Aufhebung des Schutzes zu bewirken.

5. Verfahren nach Anspruch 4, gekennzeichnet dadurch, daß das Volumsverhältnis von Anisol zu Thioanisol ungefähr 20:80 bis 80:20 beträgt.

6. Verfahren nach Anspruch 4, gekennzeichnet dadurch, daß das Volumsverhältnis von Anisol zu Thioanisol ungefähr 1:1 beträgt.
7. Synthese in der festen Phase von Thymosin α_1 - das Polypeptid hat die Sequenz :

Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-
Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH

- indem das Polypeptid gebildet wird, welches obenstehende Sequenz an ein Harz angehängt aufweist, und das besagte Polypeptid eine oder mehrere geschützte Funktionalgruppen besitzen kann, und weiters indem das Polypeptid vom Harz abgespalten und der Schutz von geschützten Gruppen aufgehoben wird, gekennzeichnet dadurch, daß Methylbenzhydrylamin-Harz verwendet wird und die Abspaltung beziehungsweise die Aufhebung des Schutzes des Polypeptides durch Kontakt des Polypeptides mit Wasserstoffbromid erreicht wird.

8. Verfahren nach Anspruch 7, gekennzeichnet dadurch, daß die Abspaltung und die Aufhebung des Schutzes des Polypeptids, welches an Methylbenzhydrylamin-Harz gebunden ist, mit Hilfe einer Mischung von anhydriertem Wasserstoffbromidgas in Trifluoressigsäure durchgeführt wird.

9. Verfahren nach Anspruch 8, gekennzeichnet dadurch, daß die Mischung zusätzlich Anisol aufweist.


10. Verfahren nach Anspruch 9, gekennzeichnet dadurch, daß die Mischung zusätzlich Thioanisol aufweist.

11. Verfahren nach Anspruch 10, gekennzeichnet dadurch, daß das Volumsverhältnis von Anisol zu Thioanisol von ungefähr 1:4 bis 4:1 beträgt.

12. Verfahren nach Anspruch 11, gekennzeichnet dadurch, daß das Volumsverhältnis von Anisol zu Thioanisol ungefähr 1:1 beträgt.

Revendications

1. Procédé de synthèse peptidique en phase solide, pour la production d'un peptide amide, dont la séquence d'acides aminés est représentée par la formule :



dans laquelle :

Y_p représente le fragment peptidique N-terminal ayant au moins 2 acides aminés liés ensemble par des liaisons peptidiques ; et

$X-NH_2$ représente l'acide aminé C-terminal ayant un groupe amide ($-CONH_2$) dans sa structure moléculaire,

par formation du peptide ayant la séquence ci-dessus lié à une résine, ledit peptide ayant facultativement un ou plusieurs groupes fonctionnels protégés, et clivage du peptide à partir de la résine et déprotection des groupes fonctionnels protégés, caractérisé par le fait que le peptide est formé par liaison à une résine substituée par méthylbenzhydrylamine et clivage et déprotection du peptide lié à la résine par du bromure d'hydrogène.

2. Procédé selon la revendication 1, dans lequel le peptide lié à la résine substituée par méthylbenzhydrylamine est mis en suspension dans de l'acide trifluoroacétique, et du bromure d'hydrogène anhydre gazeux est insufflé dans la suspension pour effectuer le clivage et la déprotection.

3. Procédé selon la revendication 1, dans lequel un mélange de bromure d'hydrogène gazeux et d'anisole est utilisé pour effectuer le clivage et la déprotection.

4. Procédé selon la revendication 1, dans lequel un mélange de bromure d'hydrogène, d'anisole et de thioanisole est utilisé pour effectuer le clivage et la déprotection.

5. Procédé selon la revendication 4, dans lequel le rapport en volume de l'anisole au thioanisole est d'environ 20:80 à environ 80:20.
6. Procédé selon la revendication 4, dans lequel le rapport en volume de l'anisole au thioanisole est d'environ 1:1.
7. Synthèse en phase solide de la thymosine α_1 , polypeptide ayant la séquence :

Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-
 Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-
 Glu-Glu-Ala-Glu-Asn-OH,

par formation du polypeptide ayant la séquence ci-dessus ancré à une résine, ledit polypeptide ayant facultativement un ou plusieurs groupes fonctionnels protégés ; et clivage du polypeptide à partir de la résine et déprotection des groupes fonctionnels protégés du polypeptide ; caractérisée par l'utilisation d'une résine substituée par méthylbenzhydramine et clivage et déprotection du polypeptide par mise en contact du polypeptide avec du bromure d'hydrogène.

8. Procédé selon la revendication 7, dans lequel le polypeptide lié à la résine substituée par méthylbenzhydramine est clivé et déprotégé par un mélange de bromure d'hydrogène anhydre gazeux dans l'acide trifluoroacétique.
9. Procédé selon la revendication 8, dans lequel le mélange comprend en outre de l'anisole.
10. Procédé selon la revendication 9, dans lequel le mélange comprend en outre du thioanisole.
11. Procédé selon la revendication 10, dans lequel le rapport en volume de l'anisole au thioanisole est d'environ 1:4 à environ 4:1.
12. Procédé selon la revendication 11, dans lequel le rapport en volume de l'anisole au thioanisole est d'environ 1:1.

REGISTER ENTRY FOR EP0200404/

European Application No EP86302731.4 filing date 11.04.1986 /

Priorities claimed:

11.04.1985 in United States of America - doc: 722218
09.04.1986 in United States of America - doc: 849835

Designated States BE CH DE FR GB IT LI LU NL SE AT

Title SOLID PHASE PROCESS FOR SYNTHESIZING PEPTIDES

Applicant/Proprietor

see ①³
ALPHA-1 BIOMEDICALS, INC./, 777 14th Street, N.W. Suite 774, Washington,
D.C. 20005, United States of America [ADP No. 50326495001]

Inventor

SU SUN WANG, 1512 Chula Vista Drive, Belmont California 94002, United
States of America [ADP No. 54405204001]

Classified to

C3H U1S
C07K

Address for Service

WILLIAM GORDON ADAMS, RAWORTH, MOSS & COOK 36 Sydenham Road, Croydon
Surrey CR0 2EF, United Kingdom [ADP No. 50305960001]

EPO Representative

WILLIAM GORDON ADAMS, RAWORTH, MOSS & COOK 36 Sydenham Road, Croydon
Surrey CR0 2EF, United Kingdom [ADP No. 50305960001]

Publication No EP0200404 dated 05.11.1986

Publication in English

Examination requested 11.04.1986

Patent Granted with effect from 30.06.1993 (Section 25(1)) with title SOLID
PHASE PROCESS FOR SYNTHESIZING PEPTIDES./

26.08.1988 EPO: Search report published on 31.08.1988

Entry Type 25.11 Staff ID.

Auth ID. EPT

**** END OF REGISTER ENTRY ****

OA80-01
EP

OPTICS - PATENTS

05/11/96 11:28:15
PAGE: 1

RENEWAL DETAILS

PUBLICATION NUMBER

EP0200404 /

PROPRIETOR(S)

see ①³
ALPHA-1 BIOMEDICALS, INC. / 777 14th Street, N.W. Suite 774,
Washington, D.C. 20005, United States of America

DATE FILED

11.04.1986 /

DATE GRANTED

30.06.1993 /

DATE NEXT RENEWAL DUE

11.04.1997

DATE NOT IN FORCE

DATE OF LAST RENEWAL

02.04.1996

YEAR OF LAST RENEWAL

11

STATUS

PATENT IN FORCE /

**** END OF REPORT ****